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Human papilloma virus vaccination programs
reduce health inequity in most scenarios: a
simulation study
Natasha S Crowcroft1,2,3*, Jemila S Hamid1,4,5, Shelley L Deeks1,3 and John Frank6,7,3
Abstract
Background: The global and within-country epidemiology of cervical cancer exemplifies health inequity. Public
health programs may reduce absolute risk but increase inequity; inequity may be further compounded by
screening programs. In this context, we aimed to explore what the impact of human papillomavirus (HPV) vaccine
might have on health equity allowing for uncertainty surrounding the long-term effect of HPV vaccination
programs.
Methods: A simple static multi-way sensitivity analysis was carried out to compare the relative risk, comparing after
to before implementation of a vaccination program, of infections which would cause invasive cervical cancer if
neither prevented nor detected, using plausible ranges of vaccine effectiveness, vaccination coverage, screening
sensitivity, screening uptake and changes in uptake.
Results: We considered a total number of 3,793,902 scenarios. In 63.9% of scenarios considered, vaccination would
lead to a better outcome for a population or subgroup with that combination of parameters. Regardless of vaccine
effectiveness and coverage, most simulations led to lower rates of disease.
Conclusions: If vaccination coverage and screening uptake are high, then communities are always better off with a
vaccination program. The findings highlight the importance of achieving and maintaining high immunization
coverage and screening uptake in high risk groups in the interest of health equity.
Background
Cervical cancer exemplifies health inequity, both within
nations and globally [1]. Inequities have persisted even
within countries with good screening programs; there is
hope that primary prevention through vaccination may
address this [2]. A substantial body of work has indi-
cated significant benefits and cost-benefits of vaccination
against the infectious cause of cervical cancer, human
papilloma virus (HPV) [3,4]. Two vaccines are available
to protect against genotypes responsible for about 70%
of cervical cancers [5]. These vaccines have been found
to be very efficacious and safe and programs have been
implemented in various countries throughout the world,
including Canada, Australia, the United Kingdom and
the United States. HPV vaccination programmes have
nevertheless aroused some controversy. The vaccine is
expensive, raising questions about alternative public
health gains in countries with existing cervical cancer
screening programs, which could have been obtained for
the same investment. Non-substantiated fears have been
raised by some, about the impact of the vaccine on sex-
ual behaviour; parents who believe the vaccine might
have a negative influence on sexual behaviour are less
likely to intend to vaccinate daughters [6]. Other com-
mentators [7] have pointed out that this vaccine is
unique, in that it could potentially lead to the decreased
utilization of the cervical screening program, already
established as effective, by women unclear about the
vaccine’s incomplete coverage of oncogenic viral geno-
types, [8,9], thereby paradoxically increasing the future
burden of invasive cervical cancer from the much less
common non-vaccine strains. It is important to note that
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cervical screening is not primary prevention since it pro-
vides early detection of cervical abnormalities; it is only
effective among women who participate in the program
and there are well documented social inequities regard-
ing program participation [10-12].
There are a number of uncertainties, inevitable with
any new vaccine, which require careful monitoring of
the “natural experiment” currently taking place in juris-
dictions such as Canada, where different schedules for
publicly funded HPV vaccination programs have been
implemented at different times and for age groups
ranging from grade 4 to 8 (ages 9–13 years) [13]. The
programs are all being delivered to girls by public health
through schools, however the school grade targeted var-
ies throughout the country. Surveillance of all aspects of
new vaccination programmes - adverse events, coverage,
attitudes and disease incidence – is essential. One of
several reasons for this is that vaccination programmes
may have paradoxical effects in increasing burden of
disease [14] and inequity in health [15]. However, as the
vaccine is delivered through school-based programs, and
children in Canada are legally required to attend schools,
inequity may be diminished. In the context of uncer-
tainty about key parameters such as duration of vaccine
protection, and the impact of the programme on behav-
iour related to screening uptake, the question arises
whether there are realistic scenarios in which HPV
vaccination programmes could cause relative or absolute
harm to particular groups in society.
A root cause of inequity in cervical cancer is poverty,
mediated biologically by increased risk of sexual expos-
ure to HPV and reduced detection, appropriate follow-
up and treatment for preclinical abnormalities. Cervical
cancer is also a disease of poverty via psycho-social
mechanisms, such as a lack of power for women around
sexual relations (in many societies, but generally asso-
ciated particularly with lower levels of female education)
and lack of understanding of the disease [16].
Although current vaccines protect against two of the
HPV types which cause around 70% of cervical cancers,
another 13 types are established high-risk and a further
3 are probably high-risk [5]. Because of these other
types, as well as the fact that no vaccine is 100%
effective, cervical cancer screening programmes need to
continue in some form, regardless of vaccination pro-
grammes [5,17]. Implementation of such “competing”
programmes (in the sense that they may compete for the
attention and compliance of women at risk) may harm
some groups if, post-vaccination, behavioural changes
either increase the risk of acquisition of non-vaccine
oncogenic HPV types, or reduce the uptake of effective
screening and follow-up treatment of pre-clinical abnor-
malities. An additional possible issue would be that as
more advanced lesions become rarer, high-volume Pap-
smear cytologists may become less adept at recognizing
them. These perverse effects may be potentiated if the
extent and/or duration of vaccine effectiveness is lower
than anticipated (data on the long-term duration of
protection are currently accumulating and are approxi-
mately five years ahead of vaccination programs). Benefi-
cial effects of vaccination may, on the other hand, be
potentiated, if the vaccine confers significant indirect
(“herd”) protection by reducing the circulation of the
HPV vaccine strains or if it confers protection for
women who would not have participated in the screen-
ing program. The overall impact of a vaccination
programme on the risk of cervical cancer thus depends
on the interplay of several factors. We aimed to find out
whether it is possible using a simple approach to dis-
cover plausible scenarios in which corresponding popu-
lation subgroups could be at increased risk of invasive
cervical cancer following the implementation of an HPV
vaccination programme, thereby potentially increasing
inequity in the whole population.
Methods
We carried out a multi-way sensitivity analysis using a
simple static mathematical model developed to assess
the impact of different prevention strategies on cervical
cancer relative to the state before a vaccination program
was implemented. The simulation generates a number of
scenarios representing a set of conditions that might
apply to a particular subgroup of the population. The
terms scenario and subgroup are therefore used inter-
changeably below.
We considered each of many possible subgroups of
the population, defined by specific values of several vari-
ables that co-determine invasive cervical carcinoma risk,
and estimated whether each subgroup would be better
or worse off with a vaccination programme in place,
given the presence of cervical screening. The parameters
were varied within a wide range that included plausible
values to allow for different characteristics of risk groups
in any population (Table 1). The possible impact of HPV
vaccination programmes for teenage girls on the preva-
lence of circulating vaccine strains through herd immun-
ity is currently unknown. We estimated indirect effects
at exposure reductions of 60%, 40% and 20%. Vaccine ef-
fectiveness was considered between 50% and 90%. The
lower end of the range for the vaccine effectiveness value
was set at 50% to allow for possible waning of immunity
during mid-adult life, to capture longer-term effective-
ness, as opposed to efficacy, of the vaccine. Mid-adult
life is a time when sexual activity for many women still
leads to HPV exposure, with increasing rates of break-
down of marital relationships and new sexual partner
initiation in later years [18], and given that many years
will have elapsed since they were vaccinated by the pre-
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pubertal programs now in place. In published dynamic
models, vaccine efficacy has been estimated at 90-100%
[19-21]. The duration of immunity is unknown and will
likely depend in part on frequency of ongoing exposure
to HPV and whether this provides immunological boost-
ing. For other viral vaccines such as measles, vaccine-
derived immunity has been shown to decline more rap-
idly than natural immunity, at least in part due to the
success of programs in eliminating viral circulation and
boosting. Cross protection against other genotypes was
not included in the model. We investigated coverage in
the range of 20%-90% to account for high coverage in
some developed countries and low coverage in some
developing countries (this may be true for some religious
and other subgroups as well). Baseline screening sensi-
tivity was previously estimated to be 59% [10] - we,
therefore, focus on this level of baseline sensitivity when
presenting the results of our simulation study, although
a similar range of estimates as used for vaccine effective-
ness was also considered. Lifetime screening participa-
tion of between 10% and 90% was investigated.
Model Parameters
R: Risk of infections which would cause invasive
cervical cancer if neither prevented nor detected
V: Vaccine effectiveness
C: Vaccination coverage
S: Screening uptake prior to the introduction of the
program
E: Baseline lifetime screening sensitivity
(the sensitivity of the screening program)
δPv: Proportional change in risk (R) caused by
vaccine strains if neither prevented nor detected,
occurring as a result of herd immunity or
behavioural change
δPu: Proportional change in risk (R) caused by non-
vaccine strains if neither prevented nor detected,
occurring as a result of behavioural change or
strain replacement
δS: Proportional change in screening uptake
δE: Proportional change in lifetime screening
sensitivity
R1: Risk of undetected infections which would cause
invasive cervical cancer for a woman living in a
population without a vaccination programme
R2: Risk of undetected infections which would cause
invasive cervical cancer for a woman living in a
population with a programme
For a woman living in population without a vaccin-
ation programme, risk of undetected infections which
would cause invasive cervical cancer can be estimated as
R1 ¼ R  1 S  Eð Þ
However, for a woman under the vaccination program,
the risk of getting these life threatening infections can
be described as
R  1þ δPυþ δPuð Þ;
Where, δPv and δPu are changes (increases or
decreases) attributed to vaccine or non-vaccine strain
exposures.
Risk reduction due to vaccination is estimated as,
0:7  R  C  V þ δPυ  RC  V ¼ R  C  V  0:7þ δPυð Þ;
Where 0.7 accounts for the protection obtained from
currently available vaccines against two of the HPV types
which cause approximately 70% of cervical cancers.
Therefore, the risk of undetected infections can now
be given as
R  1þ δPυþ δPuð Þ  R  C  V  0:7þ δPυð Þð Þ
¼ R  1þ δPυþ δPuð Þ  C  V  0:7þ δPυð Þð Þð Þ
Similarly, changes in uptake of screening and of the ef-
fectiveness of screening can be incorporated in the esti-
mates, consequently, R2 becomes
R2 ¼ R  2þ δPυþ δPuð Þ  C  V  0:7þ δPυð Þð
1 S  E  1þ δSð Þ 1þ δEð Þð Þð Þ
Table 1 Ranges of parameters considered in the
simulation study
V C S E δPv δPu δS δE
90% 90% 90% 90% −0.6 −0.6 −0.6 −0.6
80% 80% 80% 80% −0.4 −0.4 −0.4 −0.4
70% 70% 70% 70% −0.2 −0.2 −0.2 −0.2
60% 60% 60% 60% 0 0 0 0
50% 50% 50% 50% 0.2 0.2 0.2 0.2
40% 40% 0.4 0.4 0.4 0.4
30% 30% 0.6 0.6 0.6 0.6
20% 20%
10%
V =Vaccine effectiveness.
C = Vaccination coverage.
S = Screening uptake.
E = Baseline lifetime screening sensitivity (the sensitivity of the screening
program).
δPv = Proportional change in the risk of infections caused by vaccine strains
which would cause cervical cancer if nether prevented nor detected.
δPu = Proportional change in the risk of infections caused by non-vaccine
strains which would cause cervical cancer if nether prevented nor detected.
δS =Proportional change in screening uptake.
δE = Proportional change in lifetime screening sensitivity.
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The relative risk can then be given as
If the relative risk (RR) is less than 1 then the outcome
of the vaccination programme was considered to be bet-
ter and if greater than or equal to 1, then the outcome
of vaccination was worse than the previous state. Vac-
cine adverse events were not included in the analysis,
and the vaccine is relatively expensive, so that R1=R2
with a vaccination programme was not considered a sat-
isfactory outcome. On the other hand, early indications
are that the vaccine is safe and well tolerated with the
only excess adverse event reported so far being anaphyl-
axis, with a number needed to harm (NNH) of around
40,000 per dose [22]. Similarly, adverse effects of screen-
ing were also not included in the analysis.
Our primary outcome of interest is the percentage of
scenarios/subgroups, of the all possible combinations of
parameter values which are considered, in which RR ≥ 1.
The actual percentage is less important than the trends
across different levels of parameters and the range of
scenarios in which the outcome is not better with a vac-
cination program. We are interested in scenarios in
which subgroups may be worse off as an indicator of the
extent to which vaccination programs may result in in-
equity. These scenarios also represent the situations in
which certain characteristics and circumstances may
cluster to cause disadvantage to population subgroups
and hence create inequity.
Applying the range of parameters considered in the
simulation (Table 1), the number of possible combina-
tions is 8*9*5*7*7*7*7= 864,360 for each level of vaccine
effectiveness, giving a total of 4,321,800 scenarios. How-
ever, we removed 527, 898 scenarios that led to zero or
negative risk as being practically irrelevant although they
are mathematically valid. This occurs when (1 + δS) *
(1 + δE) ≥ 1/(E * S), and one such example is when
baseline screening uptake and sensitivity are set to
70% and 80% , respectively while change in uptake
and sensitivity are allowed to be 0.6. This leads to sce-
narios which are unrealistic, which are thus removed
from our analysis/investigation. Therefore, the total
number of subgroups/scenarios investigated in our
paper 3,793,902. In addition we carried out sensitivity
analyses to see the impact of two variables at a time
in different scenarios. The simulation and data analysis
is performed in the R statistical package [23].
Results
The results from our simulation study show that the
outcome of vaccination would be better in the majority
of scenarios/subgroups (RR<1 in 63.9% of scenarios con-
sidered) but worse in a substantial proportion of scenar-
ios considered (RR ≥1 in 36.1% of the scenarios). The
distribution of RR is heavily skewed to the left (the dir-
ection of a beneficial effect), where RR < 1.2 for more
than 75% of the scenarios considered, RR > 2 for less
than 5% of the scenarios and less than 1% of the scenar-
ios result in RR >3 (Figure 1). This indicates that in most
scenarios, the population subgroup benefits from the
vaccination programme. This is consistently observed in
our simulation regardless of vaccine effectiveness and
coverage although the actual percentage values vary with
each (Table 2, Figures 2,3,4 and 5).
As expected, the benefit of the vaccine programme
increases as vaccine effectiveness and coverage increase,
indicating that achieving and maintaining high coverage
is important in all subgroups to get a maximal benefit
from the vaccine program. This is true regardless of vac-
cine effectiveness. When vaccine effectiveness is set at
50% (well below current estimates), while other popula-
tion parameters are allowed to vary, 59.3% of the scenar-
ios still result in a beneficial outcome with RR < 1. The
distribution remains heavily skewed to the left. Only 6%
of the populations had RR > 2 and RR > 3 for about 1%
of the scenarios. Similarly, for vaccine effectiveness of
90%, 68.4% of the populations result in RR < 1 and RR >
1 was obtained for 31.6% of the population, RR < 1.2 for
RR ¼ R2
R1
¼ 1þ δPυþ δPuð Þ  C  V  0:7þ δPυð Þð Þ  1 S  E  1þ δSð Þð Þð Þ
1 S  E
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Figure 1 The distribution of RR when all the eight parameters
considered are allowed to vary within the range provided in
Table 1.
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79% of the populations, RR > 2 for less than 3% of the
populations and less than 1% of the scenarios result in
RR > 3.
When vaccine effectiveness is set at 90% and coverage
is very low (20%), the percentage of scenarios in which
the population might be worse off with a vaccination
programme is quite high (45%) although the relative risk
is still less than 1.2 for 66% the scenarios. However,
when coverage is increased to 70%, the percentage of
scenarios that are worse off decreases substantially
(25.1%). For 90% coverage, the percentage of scenarios
in which populations could potentially be worse off is
only 18.8%, and the percentage of scenarios with RR <
1.2 increased to 90.6%. Table 2 shows the distribution of
RR for different values of vaccine effectiveness and
coverage. Figures 2, 3, 4 and 5 show the impact of vary-
ing coverage and screening uptake or changes in screen-
ing uptake and reinforce the baseline screening level and
coverage to be the most important factors to consider.
Note that the effect of changes in screening uptake or
Table 2 Distribution of relative risk (RR) at different
levels of vaccine effectiveness (V) and coverage (C)
V C Percentage of Scenarios
RR < 1 RR < 1.2 RR > 1 RR > 2 RR > 3
90 20 54.92 66.21 45.08 7.70 1.52
50 66.94 77.60 33.06 3.59 0.71
70 74.92 84.89 25.08 2.05 0.39
90 81.25 90.58 18.75 1.25 0.22
70 20 53.14 64.46 46.86 8.61 1.71
50 63.01 73.79 36.99 4.73 0.95
70 69.05 79.44 30.95 3.19 0.62
90 74.92 84.89 25.08 2.05 0.39
50 20 51.44 62.78 48.56 9.48 1.91
50 58.28 69.42 41.72 6.3 1.25
70 63.01 73.79 36.99 4.73 0.95
90 66.94 77.60 33.06 3.59 0.71
Footnote: If RR>1, the outcome is worse in that scenario/subgroup.
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Figure 2 Percentage of scenarios in which a subgroup might
be worse off, for different levels of coverage and baseline
screening uptake. Vaccine effectiveness is set at 90% and baseline
sensitivity is set at 60%. Other variables are allowed to vary within
the range provided in Table 1.
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Figure 3 Percentage of scenarios in which a subgroup might
be worse off, at different levels of change in screening uptake.
Vaccine effectiveness and coverage are set at 90%, and screening
sensitivity is maintained at 60%.
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Figure 4 Percentage of scenarios in which a subgroup might
be worse off in a scenario where baseline screening is high,
according to coverage and different levels of change in
screening uptake. V=90%, E=60%, S=80%, the rest of the variables
are assumed to vary according to Table 1.
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sensitivity would be identical because our formula is
symmetrical.
The proportion of scenarios in which RR<1 was lower
if screening uptake was higher at baseline and then
declined (Table 3, Figures 2, 3). If screening participation
is maintained at baseline levels, whatever they may be,
and vaccine coverage is high, the outcome is good in all
scenarios (Table 3).
The greater the increase in non-vaccine strains, the
greater the proportion of scenarios with a worse out-
come, reaching 30% of scenarios if non-vaccine strains
increased by 40%. However, if non-vaccine strains
increased by only 20%, the population is better off in
90% of scenarios. Our simulation results indicate that
the percentage of scenarios that are worse off can be
reduced further if coverage, screening uptake and sensi-
tivity are maintained or increased (Figures 2, 3 4 and 5).
While baseline screening uptake, sensitivity and the risk
of infection prior to introduction cannot be changed and
vaccine effectiveness is also a fixed characteristic of the
program, changes in screening uptake after introduction
and vaccination coverage are amenable to intervention
so the finding that these are also the critical elements in
a sensitivity analysis is important.
Proportional improvements in cytological screening ef-
fectiveness reduced the number of scenarios in which
sub-populations might be worse off with a programme
(data not shown). The effect was more modest in the
different baseline screening scenarios when vaccine ef-
fectiveness was set at 90%, but for every level of screen-
ing effectiveness the proportion of scenarios in which
the outcome was worse, after vaccination, remained very
small as long as coverage is high and screening uptake is
maintained.
Discussion
This analysis is very simplistic and aims as much to raise
the issue of consequences, for different groups in society,
as to yield precise estimates of program effectiveness. It
should be regarded as an exploratory sensitivity analysis
and the basis for further work. More sophisticated
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Figure 5 Percentage of scenarios in which a subgroup might
be worse off in a scenario where baseline screening is high,
according to coverage and different levels of change in
screening uptake. V=90%, E=60%, S=20%, the rest of the variables
are assumed to vary according to Table 1.
Table 3 Percentage of scenarios in which a subgroup
might be worse off at different levels of baseline
screening uptake
S δS Percentage of Scenarios
E = 60% E = 90%
δE≠0 δE=0 δE≠0 δE=0
20 −0.6 19.41 17.95 23.08 23.08
−0.4 16.12 15.38 19.05 17.97
−0.2 13.92 12.82 15.75 12.82
0 11.36 10.27 10.99 10.26
0.2 9.89 10.26 9.52 7.69
0.4 7.69 7.69 6.96 5.13
0.6 6.28 5.13 5.49 0
50 −0.6 29.67 28.21 41.39 43.59
−0.4 24.54 25.64 32.60 33.33
−0.2 17.95 17.95 22.71 25.64
0 12.45 10.26 16.11 10.26
0.2 9.89 5.13 11.72 0
0.4 7.33 0 10.25 0
0.6 5.86 0 7.91 0
70 −0.6 38.83 41.03 56.41 58.97
−0.4 30.77 30.77 44.69 48.72
−0.2 21.61 23.08 30.77 35.90
0 15.02 10.26 24.59 10.26
0.2 10.98 0 20.46 0
0.4 8.42 0 16.67 0
0.6 6.97 0 15.92 0
90 −0.6 49.08 48.72 75.46 76.92
−0.4 37.73 41.03 62.27 66.67
−0.2 26.01 28.21 47.95 53.85
0 18.32 10.26 37.67 10.26
0.2 15.16 0 33.87 0
0.4 12.56 0 30.57 0
0.6 11.83 0 32.03 0
S = Screening uptake.
E = Baseline screening sensitivity (the sensitivity of the test).
δS =Proportional change in screening uptake.
δE = Proportional change in screening sensitivity.
Coverage and vaccine effectiveness are set at 90%, baseline sensitivity is set at
60% and 90%.
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approaches such as Monte Carlo simulations may be
more methodologically pure, but perhaps less intuitive
and thus more “black box” than our approach of trying
out all combinations of parameter values, within what
seem to be plausible ranges. We have not estimated a
“prior” probability distribution for our parameters, as
Bayesian methods would require, and so have remained
in a state of equipoise in relation to the likelihood of
these different possible future scenarios. This is a signifi-
cant limitation since we know that some parameter
values are much more likely than others, and that some
values of different parameters which combine either to
increases or decrease risk are more likely to occur in
combination. Established risk factors (such as multi-
partner, unprotected sexual behaviour from early in
teenage life; failure to take up preventive health care -
including vaccination and regular cytological screening;
early smoking; and poverty) tend to cluster, as do protect-
ive factors, among various socioeconomic subpopulations,
as well as certain ethnic groups in some societies. The
overall effect of ignoring this non-independence of risk
factor distributions in the population - i.e. clustering - is
likely to make this analysis conservative with respect to
the proportion of scenarios modelled in which the corre-
sponding subgroup is substantially worse off – or much
better off – after vaccination, since risk-factor clustering
would tend to increase the variance of the modelled
overall-risk distribution, leading to a larger number of
scenarios, and corresponding fractions of most populations,
with much worse-than-average and better-than-average
results. In other words, this analysis may tend to under-
estimate the extent to which vaccination may result in
inequity.
Unlike many other vaccines, even if the herd immunity
effect led to an indirect impact on invasive cancer of
vaccine strains, the outcome could still be poorer in
some scenarios in which a subgroup of the population
may find itself, because the overall impact of the pro-
gram depends on other factors, including screening up-
take and the prevalence of non-vaccine genotypes. But
such scenarios remain in the minority. For instance, if
the prevalence of circulating vaccine strains fell by 60%,
then the outcome would be better for 88% of subgroups,
as long as vaccination effectiveness and coverage were
fixed at 90%. If the fall in vaccine strain prevalence were
only 20% then the outcome would still be better in 82%
of scenarios, showing that if herd immunity effects are
modest this could be compensated for by declines in
other parameters. Although many vaccination pro-
grammes result in herd immunity which protects every-
one, vaccinated or not, they may not benefit everyone
equally and, indeed, may increase inequity in health.
Such iatrogenic inequity receives less attention than in-
equities observed in other areas of public health because
the overwhelming success of vaccination programmes
produces such a large absolute reduction in most indivi-
duals’ (and therefore the population-level) risk of dis-
ease. Although not addressed in the current study,
adding males to the vaccination programme would have
an impact on herd immunity and therefore a further
benefit to women. Furthermore, the delivery of vaccine
through schools, rather than primary care, may also
balance the overall impact of the program in favour of
increasing equity. HPV is highly transmissible, implying
that to achieve significant herd immunity will require
not only high effectiveness but also coverage that is
significantly higher than the levels of around 50% seen
jurisdictions such as Ontario [24,25].
Conclusions
Redressing health inequity is a central theme in public
health [16]. A sound conceptual framework and good
information are required to quantify the impacts of all
interventions’ impacts on such inequity, and to robustly
evaluate any further program or policy modifications to
avert particularly inequitable impacts. This simplistic
analysis indicates that the population or sub-populations
would be better off with a vaccination program than with-
out one in most scenarios. In some unlikely circumstances,
they may, however, be worse off with an HPV vaccination
programme than without one. Ensuring that at least one
person is better off while nobody is worse off after such
programs are implemented (in economists’ terms, Pareto
improvement) requires not only high coverage of vaccin-
ation but also good uptake of screening programmes in
those groups most at risk. To ensure both requires com-
prehensive and linked information systems for monitoring
vaccination coverage, screening registries (which ideally
include information on HPV infection at a type-specific
level), and cervical cancer screening uptake. This analysis
suggests that to be safe and equitable, jurisdictions with
vaccination programmes should aim to ensure that, in the
absence of long-term data on vaccine effectiveness,
coverage in all groups should be greater than 60% and that
cervical screening uptake is high and sustained in all
groups. The lesson from cervical screening programs is,
like many screening programs, that they may increase
health inequity [26]. Vaccination programmes delivered
through schools may be better poised to decrease health
inequities, as school attendance is mandatory and partici-
pation does not rely on attendance at an off-site health
clinic. Regardless, systems need to have the capacity to
identify groups at highest risk for paradoxical negative
combined effects of screening programs and HPV vaccin-
ation, and to be linked to actions to effectively mitigate
those risks. Some jurisdictions have rightly set aside
resources for evaluation; those without systems in place
are hoping for the best but not preparing for the worst.
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